Luke Evnin Sells 28,009 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 28,009 shares of the stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $1.07, for a total value of $29,969.63. Following the completion of the sale, the director owned 2,907,986 shares of the company’s stock, valued at approximately $3,111,545.02. This represents a 0.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Luke Evnin also recently made the following trade(s):

• On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.08, for a total value of $19,286.64.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.06, for a total value of $39,330.24.
• On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.01, for a total value of $45,015.70.
• On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total value of $33,700.59.
• On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total transaction of $16,070.96.
• On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $51,813.52.
• On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.87, for a total value of $31,951.62.
• On Tuesday, December 2nd, Luke Evnin sold 38,043 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total transaction of $33,858.27.
• On Monday, December 1st, Luke Evnin sold 39,096 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $36,750.24.
• On Friday, November 28th, Luke Evnin sold 13,014 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total value of $12,883.86.

Werewolf Therapeutics Stock Up 0.9%

Shares of NASDAQ:HOWL opened at $1.10 on Friday. The company’s fifty day moving average is $1.28 and its two-hundred day moving average is $1.33. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38. The stock has a market capitalization of $53.39 million, a price-to-earnings ratio of -0.68 and a beta of 0.74.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. Equities analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Analysts Set New Price Targets

HOWL has been the topic of several recent research reports. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. JMP Securities cut their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Bank of America lowered their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Werewolf Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quadrature Capital Ltd bought a new stake in Werewolf Therapeutics during the second quarter worth approximately $28,000. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics during the 2nd quarter valued at $48,000. Nuveen LLC acquired a new position in shares of Werewolf Therapeutics during the 1st quarter valued at $71,000. AQR Capital Management LLC bought a new stake in shares of Werewolf Therapeutics in the 1st quarter worth $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth $92,000. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.